EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines
dc.contributor.author | Scheys, Joshua O. | en_US |
dc.contributor.author | Lippman, Marc E. | en_US |
dc.contributor.author | Rae, James Michael | en_US |
dc.contributor.author | Clark, Kim M. | en_US |
dc.contributor.author | Kiefer, Michael C. | en_US |
dc.contributor.author | Chadwick, Robert B. | en_US |
dc.date.accessioned | 2006-09-11T14:27:52Z | |
dc.date.available | 2006-09-11T14:27:52Z | |
dc.date.issued | 2004-09 | en_US |
dc.identifier.citation | Rae, James M.; Scheys, Joshua O.; Clark, Kim M.; Chadwick, Robert B.; Kiefer, Michael C.; Lippman, Marc E.; (2004). "EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines." Breast Cancer Research and Treatment 87(1): 87-95. <http://hdl.handle.net/2027.42/44224> | en_US |
dc.identifier.issn | 1573-7217 | en_US |
dc.identifier.issn | 0167-6806 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/44224 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15377854&dopt=citation | en_US |
dc.description.abstract | EGFRvIII is a constitutively activated truncated variant of the epidermal growth factor receptor (EGFR) which has been shown to increase tumorgenicity. There are conflicting reports on the extent of EGFRvIII expression in tissues which may in part stem from the use of different assay methodologies. We investigated the expression of both EGFRvIII and wild-type EGFR (EGFRwt) in cell lines and primary breast cancers. First, we used a RT-PCR assay that can simultaneously measure EGFRwt and EGFRvIII mRNA to screen 55 tumor cell lines. We show that except for EGFRvIII transfected cells, only EGFRwt was detected. We then validated a real-time PCR assay and used this to screen 170 formalin fixed paraffin-embedded primary breast cancers for evidence of EGFRwt and EGFRvIII expression. No samples were positive for EGFRvIII expression except for control transfectants and glioblastomas. In contrast, EGFRwt was expressed at varying levels in the majority of samples tested. We conclude that the expression of EGFRvIII is extremely rare in breast cancer and therefore it does not contribute to the malignant phenotype. | en_US |
dc.format.extent | 166625 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Clinical | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Breast Cancer | en_US |
dc.subject.other | EGFRvIII | en_US |
dc.subject.other | Epidermal Growth Factor Receptor | en_US |
dc.subject.other | Expression | en_US |
dc.title | EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbsecondlevel | Ophthalmology | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical Center, 5323 Med. Sci. 1, 1150 W. Medical Center Drive, Ann Arbor, MI, 48109-0612, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Genomic Health Inc., Redwood City, CA, USA | en_US |
dc.contributor.affiliationother | Genomic Health Inc., Redwood City, CA, USA | en_US |
dc.contributor.affiliationother | Genomic Health Inc., Redwood City, CA, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 15377854 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/44224/1/10549_2004_Article_5274918.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/B:BREA.0000041585.26734.f9 | en_US |
dc.identifier.source | Breast Cancer Research and Treatment | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.